Biologic therapies are parenteral (administered subcutaneously or intravenously) complex
proteins biologically manufactured in mammalian or yeast cell lines that typically function by …

Biologic agents have expanded the repertoire of efficacious and safe systemic therapies for
the treatment of moderate-to-severe psoriasis and active psoriatic arthritis. The biologics act …

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the
association of arthritis and psoriasis. PsA runs a variable course, from mild synovitis to …

Psoriatic arthritis (PsA) is an inflammatory disease characterised by the clinical domains of
arthritis, enthesitis, dactylitis, spondylitis, and psoriasis, often causing significant functional …

In recent years there has been a surge of interest in the treatment of chronic inflammatory
disorders as a result of the development and application of targeted biological therapies …

Clinicians often view psoriatic arthritis (PsA) as a rather minor arthritic disorder because
many are unaware of the substantial damage, disability, and reduced quality of life that …

Abstract Purpose of Review To highlight the recently approved therapeutic agents in
psoriatic arthritis (PsA), drugs in the pipeline, as well as to discuss efficacy with regard to …

Psoriatic arthritis occurs in 5-42% of patients with psoriasis. It is an inflammatory arthritis
distinct from rheumatoid, being usually sero-negative, asymmetrical and often affecting the …

Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that may affect
peripheral and axial joints, entheses, skin and nails, and other organs. Treatment with …

The pathophysiology of psoriasis and psoriatic arthritis (PsA) is dependent on a multistep
process that leads to chronic or recurrent inflammation1, 2, 3. Blockade of cytokines …